Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients

Advances in Medical Sciences

Volumn 58, Issue 2, 2013, Pages 235-243

  Lukaszewicz Zajac M ^a   Mroczko, B ^a   Guzinska Ustymowicz K ^a   Pryczynicz, A ^a   Gryko, M ^a   Kemona, A ^a   Kedra B ^a   Szmitkowski, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Gastric cancer; MMP 2; TIMP 2; Tumor marker

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; STOMACH CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTRITIS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; STOMACH NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896860345     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/ams-2013-0018     Document Type: Article

References (40)

1. Lochhead P, El-Omar EM. Gastric cancer. Br Med Bull. 2008;85:87-100.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
3. Tytgat GN. Reflections on the future of gastroenterology - unmet needs. Adv Med Sci. 2007;52:7-10.
4. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004;23(1-2):119-35.
5. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res. 2000;6(9):3581-4.
6. Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol. 1996;23(3):316-24.
7. Shim KN, Jung SA, Joo YH, Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007;42(2):120-8.
8. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002;52(4):255-64.
9. Galis ZS, Muszynski M, Sukhova GK, Simon- Morrissey E, Unemori EN, Lark MW, et al. Cytokinestimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75(1):181-9.
10. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31(1):34-45.
11. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res. 2010;85(3): 413-23.
12. Fassina G, Ferrari N, Brigati C, Benelli R, Santi L, Noonan DM, et al. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis. 2000;18(2):111-20.
13. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinaseindependent biological activities. Sci Signal. 2008;1(27):re6.
14. Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimäki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006;59(6):618-23.
15. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26(5A):3579-83.
16. Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010;31(6):549-58.
17. Partyka R, Gonciarz M, Ja?owiecki P, Kokocińska D, Byrczek T. VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Med Sci Monit. 2012;18(4):BR130-4.
18. Wu ZY, Li JH, Zhan WH, He YL. Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World J Gastroenterol. 2006;12(18): 2941-4.
19. Mönig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology. 2001;39(6):597-602.
20. Alakus H, Grass G, Hennecken JK, Bollschweiler E, Schulte C, Drebber U, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol. 2008;23(8):917-23.
21. Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci. 2000;45(1):114-21.
22. Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer. 2006;94(7):1035-40.
23. Mroczko B, Lukaszewicz-Zaj?c M, Gryko M, Kȩdra B, Szmitkowski M. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol. 2011;49(1):125-31.
24. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997;17(3C):2253-8.
25. Kanoh Y, Ohara T, Tadano T, Kanoh M, Akahoshi T. Changes to N-linked oligosaccharide chains of human serum immunoglobulin G and matrix metalloproteinase-2 with cancer progression. Anticancer Res. 2008;28(2A): 715-20.
26. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, et al. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett. 2000;151(1):81-6.
27. Jass JR, Sobin LH. WHO International histological classification of tumours. Histological typing of intestinal tumours. 2nd rev. ed. New York: Springer-Verlag;1989. 131 p.
28. Kamińska J, Kowalska M, Kotowicz B, Fuksiewicz M. Cytokiny jako niezalezne czynniki prognostyczne u chorych na nowotwory zlosliwe [The prognostic value of cytokine levels in patients with cancer]. Wspó? Onkol. 2006;10(6):259-62. Polish.
29. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics.1984;40(3):819- 25.
30. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci. 2003;94(7):569-74.
31. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis. 1994;14(1-6):234-45.
32. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9(5):899-904.
33. Zhang M, Zhu GY, Gao HY, Zhao SP, Xue Y. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. J Surg Oncol. 2011;103(3):243-7.
34. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 1996;74(3):413-7.
35. Mroczko B, Lukaszewicz-Zajac M, Groblewska M, Czyzewska J, Gryko M, Guzinska-Ustymowicz K, et al. Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue. Folia Histochem Cytobiol. 2009;47(3):511-6.
36. Emara M, Cheung PY, Grabowski K, Sawicki G, Wozniak M. Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers. Clin Chem Lab Med. 2009;47(8):993-1000.
37. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem. 1998;273(26):16098-103.
38. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem. 1999;274(30):21056-62.
39. Tan SY, Wang JY, Shen L, Luo HS, Shen ZX. Relationship between preoperative staging by endoscopic ultrasonography and MMP-9 expression in gastric carcinoma. World J Gastroenterol. 2007;13(14):2108-12.
40. Gerstein ES, Sini L, Ryabov AB, Dvorova EK, Yurchenko AA, Stilidi IS, et al. Comparative enzyme immunoassay of matrix metalloproteinases-2, -7, -9 and their tissue inhibitor-2 in tumors and plasma of patients with gastric cancer. Bull Exp Biol Med. 2009;148(6):899-902.